ArticleJournal of inflammation research2026
Zuo Gui Wan Promotes Remyelination in Multiple Sclerosis by Attenuating MAPK-Mediated Microglial M1 Polarization, an Integrated Network Pharmacology and Experimental Validation Study.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Zuo Gui Wan (ZGW) shows clinical potential in treating multiple sclerosis (MS), but its underlying mechanism of action remains elusive. This study aims to elucidate the efficacy and molecular mechanisms of ZGW in a cuprizone (CPZ)-induced demyelination mouse model. Methods: Adult male C57BL/6J mice were randomized into four groups (n = 12 each), normal control (NC), CPZ model, CPZ + 2.8 g/kg/d ZGW (ZGW-L), and CPZ + 5.6 g/kg/d ZGW (ZGW-H). Demyelination was induced by a 0.2% CPZ diet for 9 weeks. ZGW or saline was administered intragastrically from weeks 6 to 9. Behavioral performance was assessed using the rotarod, elevated plus-maze, and tail suspension tests. Remyelination was evaluated via LFB staining, TEM, and the expression of oligodendrocyte markers (Olig2, CNPase, MOG). Microglial activation/polarization (Iba-1, iNOS, CD86, Arg-1, CD206) and MAPK pathway proteins (p-ERK1/2, p-p38, and p-JNK) were quantified by Western blot or immunofluorescence. The phytochemical profile of ZGW were analyzed using LC-MS, and target prediction was performed using TCMSP, BATMAN-TCM, and SwissTarget Prediction. Network pharmacology, protein-protein interaction (PPI) analysis, and molecular docking were employed to identify core pathways and targets. Results: ZGW treatment exhibited a dose-dependent improvement in motor coordination and alleviated anxiety- and depression-like behaviors in CPZ mice. Histological and ultrastructural analyses demonstrated significantly enhanced remyelination and increased expression of Olig2, CNPase, and MOG. Network pharmacology and molecular docking analyses identified the MAPK signaling cascade as the principal therapeutic axis, with key ZGW compounds showing high affinity for MAPK3 and TNF-α. In vivo, ZGW suppressed CPZ-induced phosphorylation of ERK1/2, p38, and JNK, reduced Iba-1 expression and M1 markers (iNOS and CD86), but did not significantly alter Arg-1 or CD206. Conclusion: ZGW promotes remyelination in CPZ-induced demyelination by inhibiting MAPK pathway overactivation and attenuating microglial M1 polarization, thereby modulating the neuroinflammatory milieu.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.